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Abstract Here we describe the isolation, characterisation
and ex-vivo expansion of human epidermal neural crest
stem cells (hEPI-NCSC) and we provide protocols for their
directed differentiation into osteocytes and melanocytes.
hEPI-NCSC are neural crest-derived multipotent stem cells
that persist into adulthood in the bulge of hair follicles.
Multipotency and self-renewal were determined by in vitro
clonal analyses. hEPI-NCSC generate all major neural crest
derivatives, including bone/cartilage cells, neurons,
Schwann cells, myofibroblasts and melanocytes. Further-
more, hEPI-NCSC express additional neural crest stem cell
markers and global stem cell genes. To variable degrees and
in a donor-dependent manner, hEPI-NCSC express the six
essential pluripotency genes C-MYC, KLF4, SOX2,
LIN28, OCT-4/POU5F1 and NANOG. hEPI-NCSC can
be expanded ex vivo into millions of stem cells that remain
mulitpotent and continue to express stem cell genes. The
novelty of hEPI-NCSC lies in the combination of their
highly desirable traits. hEPI-NCSC are embryonic remnants
in a postnatal location, the bulge of hair follicles. Therefore
they are readily accessible in the hairy skin by minimal
invasive procedure. hEPI-NCSC are multipotent somatic
stem cells that can be isolated reproducibly and with high
yield. By taking advantage of their migratory ability, hEPI-
NCSC can be isolated as a highly pure population of stem
cells. hEPI-NCSC can undergo robust ex vivo expansion
and directed differentiation. As somatic stem cells, hEPI-
NCSC are conducive to autologous transplantation, which
avoids graft rejection. Together, these traits make hEPI-
NCSC novel and attractive candidates for future cell-based
therapies and regenerative medicine.
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Introduction
Neural crest-derived multipotent stem cells reside in the
periphery during embryogenesis and in the adult organism
[1–11]. One such location is the bulge of whisker follicles,
as we have shown in the Wnt1-cre::R26R mouse model in
which all neural crest cells and dorsal neural tube cells
specifically and indelibly express β-galactosidase [12–14].
According to their location in the bulge by the epidermal
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outer root sheath, the stem cells were thus termed epidermal
neural crest stem cells (EPI-NCSC). A neural crest stem
cell molecular signature comprising 19 genes that are
abundantly and uniquely expressed in mouse embryonic
neural crest stem cells and EPI-NCSC, but not in epidermal
stem cells or other skin-resident stem cells/progenitors was
subsequently defined [15]. The potential of EPI-NCSC has
begun to be realized in mouse models of spinal cord injury,
where mouse EPI-NCSC grafts led to an improvement in
sensory connectivity and touch perception [16–18]. Others
have also reported hair follicle derived progenitor cells,
both from within [19] and outside [20, 21] the bulge region,
the latter having shown promise in a model of sciatic nerve
injury. Furthermore, multipotent progenitor cells of various
ontological origin within skin and hair follicles have been
identified and have been termed skin derived precursors
(SKPs) [22–27]. Similarly, other human hair follicle-
derived neural crest-like cells formed spheres in culture
following enzymatic digestion of intact hair follicles, and
they expressed neuronal markers when injected into the
mouse brain [28, 29]. It remains to be determined whether
these cells are identical to hEPI-NCSC, as they are isolated
from entire hair follicles and do not show any migratory
behaviour. hEPI-NCSC have the distinct advantage that due
to their migratory ability they can be isolated with ease as a
highly pure population of multipotent stem cells.
The neural crest is a transient embryonic structure that
arises during neurulation at the boundary of the neural plate
and the somatic ectoderm. Neural crest cells subsequently
delaminate from the forming neural tube and migrate to
various locations in the embryo to generate a wide array of
progeny. Neural crest derivatives include craniofacial bone/
cartilage, meninges, tooth papillae, the autonomic and
enteric nervous systems, most primary sensory ganglia,
endocrine cells such as the adrenal medulla, smooth
musculature of the cardiac outflow tract and great vessels
and pigment cells (melanoyctes) of the skin and internal
organs [30, 31].
Skeletal abnormalities, bone trauma, osteoarthritis and
deteriorating joints are examples of conditions, which
severely compromise an individual’s quality of life and
ability to perform daily tasks of living. Derivation of
replacement bone and cartilage is thus of particular interest.
Osteogenic differentiation by various methods has been
reported for mesenchymal stem cells, adipose cells and
bone marrow stem cells [32–34] with others also reporting
osteogenic differentiation of neural crest stem cells derived
from human embryonic stem cells (hESC) [35], SKPs [36,
37], mouse ESC [38] and cord blood [39]. The advantage
of hEPI-NCSC is that the neural crest has the physiological
ability to generate bone, as a subset of cranial bones are of
neural crest origin [31, 40, 41]. Likewise, melanoyctes are
established neural crest derivatives. In hairy skin, they give
hair its colour by injecting melanin granules into keratino-
cytes that form new hair.
In the current study, we present an in-depth characteriza-
tion of human equivalents of mouse EPI-NCSC. By
comparison analyses, we show their neural crest origin. By
taking advantage of the migratory ability of neural crest cells,
we have developed a culture method that yields a highly pure
population of stem cells. Further studies showed that hEPI-
NCSC express all six established pluripotency markers,
which may make hEPI-NCSC a convenient source for
reprogramming into iPS cells requiring minimal manipula-
tion. Furthermore, proof-of-principle studies show that hEPI-
NCSC can undergo efficient directed differentiation into
osteocytes and melanocytes. The former are implicated in
regenerative medicine in orthopaedics, whereas the latter
could prove useful components of bioengineered skin.
Materials and Methods
Bulge Explants and Isolation of hEPI-NCSC
The bulge of adult human hair follicles [42, 43] were
micro-dissected as we have described previously [13–15]
from pubic hairy skin. De-identified biopsies were obtained
with ethical approval (REC REF: 08/H0907/1) from
consenting individuals undergoing repeat elective Caesarean
sections. The Donor age bracket was 28–41 years. Briefly,
hair follicles were dissected and mechanically cleaned of
dermal and adipose tissues. The dermal papilla and matrix
were removed and discarded, the bulge region excised, cut
into 2–3 pieces and placed onto CellStart (Invitrogen,
Paisley, UK Cat# A10142-01) coated 24-well or 35 mm
plates where they adhered to the substratum within 1 h. The
explants were incubated in a humidified atmosphere at 37°C,
5% CO2 and 5% O2. To protect cells against oxidative stress,
we routinely culture neural crest stem cells at low oxygen
tension (see e.g., ref 44). It needs to be noted that 5% oxygen
does not constitute hypoxia for hEPI-NCSC, as hypoxia is
defined as O2 tension below the normoxic value in a given
tissue [45] and oxygen tension in hair follicles ranges
between 2.5% and 0.1% O2. [46]. Culture medium was
NeuroCult XF (Stem Cell Technologies, Grenoble, France
Cat# 05761) supplemented with 10 ng/ml rhFGF2 (R&D
Systems, Abingdon, UK Cat# 233-FB), 20 ng/ml rhEGF
(R&D Systems Cat# 236-EG), 1X ITS+3 (Sigma, Poole, UK
Cat# I-2771), 1% (v/v) FBS (HyClone, Thermo Fisher,
Cramlington, UK Cat# SH30070.02), 1X GlutaMAX
(Invitrogen, Cat# 35050–038), 1X Penicillin/Streptomycin
(Sigma Cat# P0781) and 2.5 μg/ml Amphotericin B (Sigma
Cat# A2942). Four days post onset of emigration of hEPI-
NCSC, bulges were removed with a bent tungsten needle
and cells either fixed with 4% paraformaldehyde (PFA) for
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indirect immunocytochemistry as described below, or
dissolved in TRIzol® (Invitrogen, Cat# 15596–018) for
RNA isolation, or isolated by trypsinisation for sub-
culturing. Briefly, for trypsinisation, cultures were rinsed
with PBS-EDTA before addition of trypsin (Worthington
Biochemical Corporation, Lakewood, NJ, USA. Cat#
LS003703) at 500 μg/ml in PBS-EDTA. Trypsin treatment
was stopped with trypsin inhibitor (Sigma Cat# T6522;
1 mg/ml) that was dissolved in culture medium and the cell
suspension collected. The same culture medium was used for
ex vivo expansion of hEPI-NCSC.
To promote differentiation of bone/cartilage cells in
clonal culture, the culture medium was supplemented
with BMP2 (10 ng/ml). For differentiation into neuronal
cells, NGF (20 ng/ml), TGF-β2 (1 ng/ml) and forskolin
(10 μM) were added. Neuregulin-1 (10 nM) and CNTF
(10 ng/ml) were added to promote differentiation into
Schwann cells.
Real Time Quantitative RT-PCR (qPCR)
For reverse transcription, total RNA was extracted with
TRIzol® reagent and treated with DNaseI (Invitrogen Cat#
18068). cDNA was synthesised using the SuperScript III
First Strand synthesis kit (Invitrogen Cat# 18080–051),
with Oligo (dT) priming according to manufacturer’s
instructions. For quantitative real time PCR (qPCR),
reactions consisted of either RT2 Real-Time SYBR Green/
ROX MasterMix (SABiosciences/Tebu-Bio, Peterborough,
UK. Cat# 103PA-012) or SYBR Green JumpStart qPCR
MasterMix (Sigma Cat# S4438), first Strand cDNA
template and appropriate RT2 qPCR Primer Set (SABio-
sciences/Tebu-Bio). Thermo-cycling conditions were: 95°
C, 10 min followed by 40 cycles of 95°C, 15 s, 60°C, 60 s
and 70°C, 30 s, performed on an Applied Biosystems
7900HT thermocycler. Melting curve analysis showed a
single amplification peak for each reaction. Ct values for
targets were normalised to the average Ct values of four
housekeeping genes (HKG) Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), Tata box binding protein (TBP),
succinate dehydrogenase complex subunit A (SDHA) and
Glucose-6-phosphate dehydrogenase (G6PD) and
expressed as percentage thereof. Fold changes in expression
were calculated using the ΔΔCt method. Information on
primer pair sequences and source is provided in Supple-
mental Table 1. RNA from human embryonic stem cells
was used from cells of the H9 line, which was maintained
exactly as described [47].
Indirect Immunocytochemistry
Cultures were fixed with ice-cold 4% (w/v) PFA in
phosphate buffered saline (PBS, Invitrogen, Cat# 20012)
at room temperature (RT) for 30 min, followed by three
20 min PBS washes, blocked with 2% (v/v) normal goat
serum (Sigma Cat# G9023) in PBS at RT for 20 min.
Primary antibody was added, diluted appropriately in PBS,
0.1% (v/v) Triton X-100 and incubated overnight at 4°C.
Cultures were then rinsed four times with PBS for 20 min
each, followed by addition of secondary antibody diluted
1:200 in PBS and incubated in the dark for 2 h at RT.
Secondary antibody was removed and four, 20 min PBS
washes performed followed by mounting with Vectashield
plus DAPI (Vector Laboratories, Peterborough, UK Cat# H-
1500) and cover-slipped.
Primary antibodies used were: rabbit anti-MSX2
(1:200) (CeMines, Evergreen, CO, USA. Cat# AB/
HD19), rabbit anti-SOX10 (1:100) (CeMines Cat# AB/
HMG4), mouse anti-NESTIN (1:200) (BD Biosciences,
Oxford, UK. Cat# 61158), goat anti-MYO10 (1:200)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA. Cat#
SC-23137), mouse anti-ETS1 (1:200) (Santa Cruz Bio-
technology Cat# SC-56674), rabbit anti-ADAM12 (1:200)
(Santa Cruz Biotechnology Cat# SC-25579), goat anti-
CRMP1 (1:200) (Santa Cruz Biotechnology Cat# SC-
46872), goat anti-αβ-crystallin (CRYAB) (1:200) (Santa
Cruz Biotechnology Cat# SC-22391), goat anti-UFD2/
UBE4B (1:200) (Santa Cruz Biotechnology Cat# SC-
30840), goat anti-thimet oligopeptidase (THOP1) (1:200)
(Santa Cruz Biotechnology Cat# SC-30579), rabbit anti-
NANOG (1:1000) (Abcam, Cambridge, UK. Cat#
ab21624), mouse anti-KLF4 (1:100) (Abcam Cat#
ab75486), rabbit anti-LIN28 (1:1000) (Abcam Cat#
ab46020), mouse anti-SOX2 (1:100) (Abcam Cat#
ab75485), rabbit anti-OCT4 (1:1000) (Abcam Cat#
ab19857), mouse anti-C-MYC (1:200) (Abcam Cat# ab32),
mouse anti-βIII-tubulin (TUBB3) (1:200) (Millipore,
Watford, UK. Cat# MAB1637), rabbit anti-tyrosine hydroxy-
lase (TH) (1:200) (Santa Cruz Biotechnology Cat# SC-
14007), rabbit anti-alpha smooth muscle actin (SMA)
(1:200) (Abcam Cat# ab32575), mouse anti-alpha smooth
muscle actin (SMA) (1:200) (Sigma Cat# A5228), rabbit
anti-GFAP (1:1000) (Abcam Cat# ab7260), mouse anti-
collagen type II (COL2A1) (1:200) (Santa Cruz Biotech-
nology Cat# SC-59958), rabbit anti-RUNX2 (1:100) (Abcam
Cat# ab80238), mouse anti-osteocalcin (BGLAP) (1:200)
(Abcam Cat# 13418), rabbit anti-osteopontin (SPP1) (1:200)
(Abcam Cat# ab8448) and rabbit anti-DCT (1:1,000)
(Abcam Cat#ab74073).
Secondary antibodies used were: DyLight-488 conjugated
goat anti-rabbit IgG (Jackson, Newmarket, UK. Cat# 111-
485-144), DyLight-594 conjugated goat anti-mouse IgG
(Jackson Cat# 115-515-146), DyLight-488 conjugated
donkey anti-goat IgG (Jackson Cat# 705-485-147) and
DyLight-594 conjugated donkey anti-goat IgG (Jackson
Cat# 705-515-147).
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Clonal Cultures
Cells from primary explants were detached by trypsin
treatment, seeded at clonal density (60 cells per 35 mm
plate) onto CellStart treated 35 mm dishes and allowed to
attach overnight. The next morning, single cells were
identified and circled using a diamond tipped circle scribe
(circle diameter 4 mm). Single cells in circles that over-
lapped with another circle were excluded from analysis.
Greater than 90% were single cells and circles overlapped
rarely. Clones were then cultured in NeuroCult NSA (Stem
Cell Technologies, Cat# 05752), 1X ITS+3, 1% (v/v) FBS,
1X GlutaMAX, 1X Penicillin/Streptomycin and 2.5 μg/ml
Amphotericin B plus addition of specific growth factors for
differentiation of multiple cell types for up to 42 days at
37°C, 5% CO2, 5% O2. Human growth factors were from
R&D Systems; BMP2 (Cat# 355-BEC-010/CF), NGF
(Cat# 256-GF-100/CF), TGF-β2 (Cat# 302-B2-002/CF),
Neuregulin-1 (Cat# 377-HB-050/CF) and CNTF (Cat# 257-
NT-010/CF). Forskolin was from Sigma (Cat# F6886).
Cultures were fixed with 4% PFA for 30 min and
subsequently processed for indirect immunocytochemistry
as described for cell type specific markers. For serial
cloning, clones were subcloned as follows. A sterile cloning
ring was dipped into sterile vacuum grease and placed on
top of the clone. The clone inside the cloning ring was
rinsed twice with three drops of PBS each and finally three
drops of trypsin were added. The cells were then detached
by gentle trituration and re-seeded at clonal density.
Differentiation into Osteocytes
Cells were isolated by trypsinisation and seeded onto
CellStart-treated 35 mm plates at 2.5×103 cells per plate.
Cultures were grown in AdvanceSTEM osteogenic differ-
entiation medium (HyClone; Thermo Fisher Cat#
SH30877.KT), 1X GlutaMAX, 1X Penicillin/Streptomycin
and 2.5 μg/ml Amphotericin B, with 50/50 medium
exchanges on alternate days. Cultures were incubated in a
humidified atmosphere at 37°C, 5% CO2 and either 5% O2
or ambient air for up to 35 days. Alizarin Red S staining of
fixed cultures was performed to detect deposition of
calcium. Briefly, cultures were washed twice with PBS at
RT, stained for 2 h at RT with 2% (w/v) Alizarin Red S, pH
4.2 (Sigma Cat# A5533), followed by three PBS washes
and then visualised with an inverted microscope.
Differentiation into Melanocytes
For in vitro differentiation of hEPI-NCSC into melanocytes,
cells were treated with 100 nM Endothelin-3 (Sigma Cat#
E9137), 20 nM Cholera Toxin (Sigma Cat# C8052),
16.2 mM 12-O-tetra-decanoylphorbol-13-acetate (TPA)
(Sigma Cat# 79346), for up to 17 days at 37°C, 5%
CO2,10% O2. The DOPA reaction was performed to
enhance the dark melanin hue. Briefly, cultures were fixed
with 4% PFA for 20 min at RT, followed by three rinses
with PBS and incubated at 37°C with 5 mM DOPA (Sigma
Cat# D9628) for 3 h. Cells were post-fixed with 4% PFA
for 20 min at RT, rinsed with PBS and visualised with
bright field light microscopy.
Results
Bulge Explants
In order to obtain highly pure populations of hEPI-NCSC
we took advantage of their predictable migratory behaviour.
Cells with stellate morphology emigrated from bulge
explants 6–10 days post explantation (Fig. 1 and Supple-
mental document S-movie.avi). Bulges from early and late
anagen phase provided a high percentage of explants that
released emigrating cells (Fig. 1). Interestingly, the presence
of the dermal sheath was essential for a high yield of bulge
explants with emigrating cells. Bulge explants with dermal
sheath resulted in hEPI-NCSC emigration from an average
of 45.3±13.0% of cultured explants (Fig. 1 A–C, F). In
contrast, bulge explants devoid of the sheath yielded
significantly fewer emigrating cells, whereas no cells
emigrated from dermal sheath explants (Fig. 1). We have
therefore developed a reliable and highly reproducible
method for the culturing of adherent hEPI-NCSC from
dissected adult hair follicle bulge explants. It uses a
minimally invasive procedure and represents an abundant
source of neural crest-derived stem cells.
Neural Crest Origin
We have defined a neural crest stem cell signature that is
common and specific to mouse embryonic neural crest stem
cells and mouse EPI-NCSC [15]. One rationale for defining
the molecular signature was to use it for the characterisation
of human equivalent cells. The neural crest stem cell
signature is expressed in hEPI-NCSC (Fig. 2; Supplemental
Table 1). Other NCSC genes tested and detected include
SOX10, SNAI2, TWIST1, MS1 (Musashi) and p75NTR,
thus corroborating the neural crest origin of hEPI-NCSC.
Additional stem cell and the pluripotency genes SOX2, C-
MYC, KLF4, LIN28, POU5F1/OCT4 and NANOG were
expressed as well (Fig. 2; Supplemental Table 1). Equally,
the majority of hEPI-NCSC express the molecular signature
genes at the protein level as determined by indirect
immunocytochemistry (Fig. 3). The neural crest stem cell
marker SOX10 [48] and the progenitor cell marker
NESTIN were both expressed in all cells. Together, these
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observations confirm expression of pertinent markers and
characterises the bulge-derived cells as neural crest-derived
cells.
Multipotency and Self-renewal
To elicit cell differentiation in clonal cultures, clones were
treated with relevant growth factors; BMP2 for bone
differentiation, NGF, TGF-b2 and forskolin for neural
differentiation, and neuregulin plus CNTF for Schwann
cell differentiation. In clonal culture, 67.1±3.2% of clone-
forming cells generated colonies that consisted of highly
proliferative cells (Fig. 4; Supplemental Table 2). The
remaining cells either died or formed clones consisting of
4–6 non-migratory cells with the flattened morphology of
myofibroblasts. Figure 4 shows a primary clone. A single
cell is shown that generated four daughter cells within 24 h.
By day 7 the clone consisted of hundreds of migratory
cells, as seen by the changing shape of the clone. Clones
were probed with cell type-specific antibodies in all
possible permutations to show that they contained multiple
cell types and thus represented multipotent cells (Fig. 5).
The cell types were typical neural crest derivatives and
included cells with immunoreactivity characteristic of
myofibroblasts (smooth muscle actin), bone/cartilage cells
(collagen type II; COL2A1), neurons (neuron-specific βIII-
Fig. 1 Primary hEPI-NCSC emigrate from adult hair follicle bulge
cultures. (A–C) Bulge explant with cells emigrating onto the CellStart
substratum (arrows) at days 6, 8 and 10, respectively. Images are from
the same bulge explant. (D) The dermal sheath was removed from the
bulge and cultured. (E) Bulge with the dermal sheath removed in
culture. No cell emigration or proliferation was seen in D and E after
12 days in culture. (F) Percentage cell emigration by day 12 post
explanting from bulges cultured with (45.3±13.0%, n=68) and
without (6.3±6.3%, n=46) the dermal sheath and the dermal sheath
alone (0±0%, n=29). (G) Percentage cell emigration from bulges of
early anagen (stage III–IV) follicles (58.9±12.8%, n=41) and late
anagen (stages V–VI) follicles (54.4±4.3%, n=697) shows no
significant difference in cell emigration from anagen stage hair follicle
bulges. Student’s t-test. Asterisk(s) indicate levels of significant
difference as follows: *, p<0.05. Scale bars=100 μm
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Fig. 2 Stem cell gene expression by hEPI-NCSC in primary explant
and after ex vivo expansion at the RNA level and time course of
expansion. (A) Analysis by qPCR of expression levels of the neural
crest stem cell molecular signature, pluripotency genes, other neural
crest stem cell genes, general stem cell genes and early lineage genes
in primary explants (left; black) and after ex vivo expansion (right,
grey). Expression of the neural crest stem cell molecular signature and
other neural crest stem cell genes validates the neural crest origin of
hEPI-NCSC. The data from primary explants are the average of RNA
from three donors, whereas the results from ex vivo expanded cells
represent the average of two different donors. Significant differences
in expression levels are likely to be due to donor-specific differences.
Student’s t-test. Asterisk(s) indicate levels of significant difference as
follows: *, p<0.05, ***, p<0.001. (B) Growth curve of hEPI-NCSC
proliferation during ex vivo expansion. On average three million cells
per bulge were obtained within 28 days. Notably, at 28 days cell
growth has not yet levelled off but is still in the log phase. Further
expansion is thus possible. ND, not detected
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tubulin [TUBB3], tyrosine hydroxylase [TH]), and Schwann
cells (glial fibrillary acidic protein; GFAP). These observa-
tions show that multiple cell types can co-exist in the same
clone and therefore provide proof that hEPI-NCSC are
multipotent. Moreover, these data show that under suitable
culture conditions hEPI-NCSC can generate all major neural
crest derivatives.
Self-renewal is an important aspect of stemness. Self-
renewal capability of hEPI-NCSC was determined by serial
cloning. Primary clones were detached with trypsin and re-
Fig. 3 Indirect immunocytochemistry characterisation of hEPI-NCSC
shows expression of NCSC molecular signature and neural crest
markers. Staining was performed with available antibodies and
dilutions as described on hEPI-NCSC cultures for members of the
EPI-NCSC molecular signature and neural crest markers. Images
shown for corresponding stains are the antibody specific black and
white image plus the colour merged image, with DyLight 488 or
DyLight 594 fluorescence and DAPI for the nucleus as appropriate.
The transcription factor ETS1 (A and A’) was expressed in 97.3±2.7%
cells and had a nuclear localisation. THOP1 (B and B’) showed a
cytoplasmic location necessary for its roles in protein function and
metabolism and was immunoreactive in 100% of cells. MSX2 (C and
C’) is an important transcription factor involved in maintaining the
balance between survival and apoptosis in neural crest cells and
showed 98.2±1.8% expression. CRMP1 (D and D’) is located in the
cytoplasm in 98.3±1.7% of cells as it is a cytosolic phosphoprotein
involved with signal transduction pathways. UBE4B (E and E’) is
involved in ubiquitination and was seen to have a cytoplasmic
localisation in 96.7±1.6% of cells. MYO10 (F and F’) was seen to
have a cytoplasmic localisation in 97.6±2.4% of cells, consistent
with its role in cytoskeletal organisation. ADAM12 (G and G’)
showed a cytoplasmic localisation in 89.0±6.8% of cells as it is a
membrane anchored protein and has roles in cell-cell and cell-matrix
contacts. CRYAB (H and H’) is involved in intracellular structure
and subunits act as molecular chaperones and are thus localised to
the cytoplasm in 100% of cells. The intermediate filament protein
and stem cell marker NESTIN (I and I’) was seen to have a
cytoplasmic localisation and expressed in 100% of cells. The neural
crest marker SOX10 (J and J’) has a role as a nucleo-cytoplasmic
shuttle protein and was expressed in 98.6±1.4% of cells. DAPI (4′,
6-diamidine-2-phenylidole-dihydrochloride) is blue nuclear counter
stain. Scale bars=50 μm
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seeded at clonal density, which lead to secondary clones.
The procedure was repeated to establish tertiary clones.
Clone-forming ability was maintained at high levels, as
70.7±7.9% of secondary clones and 54.0±11.7% of tertiary
clones consisted of fast-growing motile cells (Supplemental
Table 2). Double stains with cell-type specific antibodies
showed that secondary clones contained multiple cell types
as well (Supplemental Figure 1). The presence of multiple
cell types in secondary clones shows that hEPI-NCSC can
undergo self-renewal. Taken together, we have thus shown
that hEPI-NCSC are multipotent stem cells.
Expression of Pluripotency Genes
hEPI-NCSC express transcripts of the six established
pluripotency genes, C-MYC, KLF4, SOX2, LIN28,
OCT4/POU5F1 and NANOG (Fig. 1 A). As this was an
unexpected finding and in order to calibrate gene expres-
sion levels, we compared pluripotency gene expression
levels with those in human embryonic stem cells (H9 cell
line). Figure 6 shows that expression profiles from cells of
different skin donors differ but that the trend is the same.
Whereas C-MYC is expressed at levels similar to H9 cells,
transcripts of the other five genes were expressed at ten to
several hundred fold lower levels than in H9 cells. SOX10
was used as a neural crest stem cell reference gene and was,
as expected, expressed at higher levels in hEPI-NCSC than
in human embryonic stem cells (Fig. 6).
Ex vivo Expansion
hEPI-NCSC can be expanded into millions of stem cells
without an overall significant loss of stem cell markers
(Fig. 2 A, B). Ex vivo expanded cells continued to express
the neural crest stem cell molecular signature, pluripotency
genes, SOX10, SNAI2, TWIST, MS1 (Musashi), P75NTR,
TERT, nestin, and some early lineages genes at the RNA
level (Fig. 2A). Expression of the neural crest stem cell
molecular signature, SOX10 and nestin, was also tested by
immunocytochemistry. All genes were expressed at the
protein level (Supplemental Figure 2). Notably, in vitro
clonal analysis showed that the majority of in vitro expanded
cells remain multipotent and thrive in clonal culture; 53.2±
3.6% of clone-forming expanded cells generated clones that
contained multiple cells types; 12.3±2.6% died and 34.5±
3.0% stopped dividing (Supplemental Figure 3). While early
lineage markers were expressed in cells from primary
explants and in ex vivo expanded cells, they were not
expressed at the protein level (see e.g., dopachrome
tautomerase; Supplemental Figure 4). The changes in gene
expression levels observed in expansion culture are likely
due to donor-specific differences (see also Fig. 6), as due to
Fig. 4 Single hEPI-NCSC in clonal cultures proliferate and form
clones. hEPI-NCSC were isolated by trypsinisation and seeded at
clonal density. Single cells were then identified and circled with a
diamond tipped circle scribe. (Day 1) Single circled cell (rectangle)
and inset, enlarged image of rectangle, (Day 2) four daughter cells
(rectangle) and inset, enlarged image of rectangle, following division
of the founder cell from Day 1. (Day 3, 4, 5 and 7) shows
proliferation of the clone after 3, 4, 5 and 7 days respectively such
that after 7 days the clone consists of many cells. The dish has been
scratched with a tungsten needle (arrow head in Day 1) and orientated
so that the field of vision is identical for each image and to show that
the clone has derived from a single cell. Arrows in Day 5 and Day 7
show dividing cells. Scale bars=100 μm
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Fig. 5 In vitro clonal analysis shows hEPI-NCSC give rise to
multiple cell types. Triple stains combining two cell type specific
antibodies (black and white) and coloured merged images using
DyLight 488 or DyLight 594 fluorescence and DAPI (blue) nuclear
stain. Stains show two cell types are present within clonal cultures. (A,
A’ and A”) Alpha smooth muscle actin (ACTA2) (arrow head),
collagen type II (COL2A1) (arrow) and merged images respectively
show cells positive for smooth muscle and bone/cartilage markers,
with COL2A1 positivity in distinct cells from ACTA2. ACTA2
staining shows a filamentous appearance consistent with its structural
role. (B, B’ and B”) ACTA2 (arrow head), βIII-tubulin (TUBB3)
(arrow) and merged images respectively. TUBB3 is a neuronal marker
and is positive in subsets of cells in addition to discrete cells being
smooth muscle actin positive. Cells positive for TUBB3 also show a
neuronal morphology with a cell body and extension of processes
(arrow). TUBB3 is seen to be expressed within the cell body and also
along the neurites. (C, C’ and C”) TUBB3 (arrow), tyrosine
hydroxylase (TH) (arrow head) and merged images respectively
shows protein expression within distinct compartments of cells, as
well as indicating that these cells may have a dopaminergic neuron
phenotype. (D, D’ and D”) TUBB3, glial fibrillary acidic protein
(GFAP) and merged images show subsets of cells positive for TUBB3
(arrow) or GFAP (arrow head). (E, E’ and E”) GFAP (arrow),
COL2A1 (arrow head) and merged images show cell type specific
staining in clonal culture.(F, F’ and F”) ACTA2, GFAP and merged
image shows many cells to be intensely ACTA2 immunoreactive
(arrow head), with discrete cells also positive for GFAP (arrow).
Scale bars=50 μm
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technical issues the data for primary explants and ex vivo
expanded cells were derived from tissue of different donors.
On average, three million cells per bulge explant were
obtained within 28 days. As illustrated in Fig. 2 B, expansion
did not level off at 28 days and therefore, if desirable, could
be continued for longer periods of time. Overall, we show
that hEPI-NCSC can be expanded ex vivo efficiently and
reproducibly and that they retain stemness. An attractive
feature of the expansion protocol is its short duration.
Changes in the karyotype are thus less of a concern in
hEPI-NCSC than in cell lines that are passaged multiple
times. The high numbers of stem cells that can be obtained
through ex vivo expansion make testing in animal models of
human disease and future applications feasible.
Directed Differentiation of hEPI-NCSC into Osteocytes
Neural crest cells give rise to various craniofacial bones.
Developing protocols for the directed differentiation of
hEPI-NCSC into osteocytes is thus an obvious first step
towards future applications of hEPI-NCSC in cell-based
therapies. Here we describe a proof-of-concept protocol for
osteogenic differentiation of hEPI-NCSC. Low oxygen
tension is the preferred way to expand neural crest stem
cells [44] and is currently an accepted culture technique for
stem cells. By contrast, in published protocols other types
of stem cell are differentiated into osteocytes at ambient
oxygen tension. We therefore compared osteogenic differ-
entiation at two different oxygen tensions, 5% O2 and
ambient air. Cultures were analyzed as primary explants
and at 7, 28 and 35 days of in vitro differentiation. Gene
expression at the RNA level was determined by qPCR and
at the protein level by indirect immunocytochemistry
(Fig. 7). Calcification was shown by histological stain with
Alizarin Red S (Fig. 7). Interestingly, transcripts of many
osteogenic early lineage markers were already expressed by
stem cells in primary explants. These included the essential
early lineage genes RUNX2 and CBFB, as well as
osteocalcin, osteopontin, collagen type 1 and vitamin D
receptor (Fig. 7). Indirect immunocytochemistry showed
intense perinuclear RUNX2 immunoreactivity by day 14
(Fig. 7 A’) in cultures at 5% O2 and at ambient oxygen
tension, respectively (Fig. 7 A”). Similar to the qPCR
results, early high RUNX2 immunoreactivity at day 14 was
followed by a decrease with progressive cell differentiation.
Both qPCR and antibody staining for collagen type II alpha
1 (COL2A1), a marker of bone/cartilage differentiation
showed an increase in expression at both O2 conditions
over the culture period (Fig. 7 B). Similarly, COL2A1
immunoreactivity was not detected until day 14 with the
expected punctuate staining pattern within the cytoplasm
(Fig. 7 B’). By day 35, COL2A1 expression levels were
similar in both 5% and ambient air (Fig. 7 B”). Transcripts
for osteopontin (SPP1), the main phosphorylated glycoprotein
of bone were already present in primary explants and
increased with progressing differentiation (Fig. 7 C). At the
protein level, osteopontin was significantly higher expressed
in cells that were cultured at ambient oxygen compared to
cells grown at 5% oxygen (Fig. 7 C”). Osteocalcin (BGLAP)
is a member of the Gla protein family and contributes to the
non-collagenous matrix in bone. Like other bone-
characteristic genes, osteocalcin transcripts were detected
already in primary explants and expression levels increased
with progressing time in differentiation culture (Fig. 7 D).
There was no significant difference in the percentage of cells
with osteocalcin immunoreactivity between the 5% oxygen
and ambient air culture conditions (Fig. 7 D”). Core-binding
factor subunit beta (CBFB) transcripts were already present
at high levels in primary explants and remained relatively
unchanged throughout the culture period at both oxygen
tensions (Fig. 7 E). qPCR for collagen type 1 alpha 1
(COL1A1) (Fig. 7 F) showed expression at low levels in
primary explants, but increased significantly to high expres-
sion levels by day 7 in both oxygen tensions. A significant
difference in expression due to oxygen tension was seen at
each time point. At the end point, collagen type 1 expression
levels were significantly higher in cells that were cultured at
5% oxygen. Unexpectedly, vitamin D receptor (VDR)
transcripts were already present at detectable levels in
primary explants (Fig. 7 G) and remained relatively
unchanged throughout the culture period with no significant
difference in expression levels at 5% and ambient oxygen at
the end of the culture period. Alizarin Red S staining, which
is an indicator of calcium deposits, was intense in cultures at
both O2 tensions (Fig. 7 H’ and H”). Overall, we show that
hEPI-NCSC can be differentiated efficiently into osteocytes
in adherent culture. Whereas individual gene expression
levels varied between 5% and ambient oxygen levels and
often differed significantly, the overall trend favours cultur-
ing at ambient oxygen tension.
Fig. 6 Expression of iPS cell genes in hEPI-NCSC compared to H9
hESC. Expression of pluripotency genes by hEPI-NCSC was
compared to H9 hESC by qPCR and the ΔΔCt method used to
determine fold differences in expression levels. Three independent
donors were assessed (Donor A-C) respectively. SOX10 was used as
a marker of neural crest stem cells and in all cases was greater
expressed in hEPI-NCSC by approximately 100 fold. C-MYC, KLF4
and surprisingly NANOG were expressed at similar levels in hEPI-
NCSC to hESC. SOX2, LIN28 and POU5F1/OCT4 were however
lower. There is also donor variation in expression levels although the
trends are similar. hEPI-NCSC from donor three were also analysed
for expression of the pluripotency genes at the protein level. Indirect
immunocytochemistry was performed with all antibody combinations
possible as labelled (A-I”). In all cases, hEPI-NCSC were immuno-
reactive for the relevant markers. Percentage expression of total cells
was determined (J); C-MYC, 100±0%, KLF4, 56.5±6.8%, SOX2,
69±4.5%, LIN28, 98.8±0.9%, POU5F1/OCT4, 95.7±1.7% and
NANOG, 92.6±3.5%. Scale bars=50 μm
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Directed Differentiation of hEPI-NCSC into Melanocytes
hEPI-NCSC were differentiated in vitro into melanocytes
by adding pertinent growth factors and reagents as
described in Materials and Methods. Before and after
DOPA reaction, pigmented cells were clearly visible
(Fig. 8, arrows), with 65.7±6% of cells positive for
melanin. Real time PCR data (Fig. 2) shows hEPI-NCSC
to express already early lineage markers for melanocytes,
including microphthalmia-associated transcription factor
(MITF) and dopachrome tautomerase (DCT), which are
important for development and function of melanocytes. In
stem cells, they were not expressed at the protein level,
whereas they were detectable in differentiated melanocytes
(Supplemetal Figure 5).
Cryopreservation
For future applications, it needs to be shown that ex vivo
expanded hEPI-NCSC can be frozen, stored frozen, thawed
and subsequently grown in culture again. We show here
that this is indeed the case. Cells were frozen in 90% FBS,
10% DMSO in a Nalgene freezing container (Sigma Cat#
C1562) to −80°C overnight and then transferred to liquid
Nitrogen. Subsequently, cells were thawed and re-cultured.
Trypan blue stain showed 87% cell viability after thawing
and the cells continued to proliferate (Supplemental
Figure 5). We thus show that hEPI-NCSC can be frozen
by inexpensive means and thawed again with high yield.
Discussion
In-depth analyses performed in this study showed that the
bulge of human hair follicles contains multipotent neural
crest-derived stem cells, which can be expanded ex vivo
Fig. 8 Directed differentiation of hEPI-NCSC into melanocytes.
hEPI-NCSC were differentiated into pigmented cells in vitro. DOPA
reaction analysis of differentiated cells confirmed expression of
pigment in 65.7±6% of cells as viewed by bright field microscopy
(arrows). Scale bar=100 μm
Fig. 7 Osteogenic differentiation of hEPI-NCSC shows expression of
key markers. hEPI-NCSC were cultured in AdvanceSTEM Osteogenic
differentiation medium at 37°C, 5% CO2 and either 5% or ambient O2
for up to 35 days. Cultures were analysed by qPCR or INDIRECT
IMMUNOCYTOCHEMISTRY for expression of osteogenic markers.
A, B, C, D, E, F and G show qPCR data for relative expression levels
compared to housekeeping genes (HKG) of the appropriate marker as
labelled. Primary culture cells (1o culture) cultured at 5% O2 as
described serve as untreated cells, with experimental cultures treated
for up to 35 days. RUNX2 (A) shows an early increase in expression
after 7 days in both O2 conditions to 85.5±0.7% and 83.4±1.6%
respectively, which then reduces over the remaining culture period.
COL2A1 (B) was seen to increase in expression with time in both O2
concentrations to a comparable final level at day 35 of 59.9±2.3% and
61.7±0.8% respectively with no expression detected in primary
culture cells. Osteopontin (SPP1) (C) was seen to show an initial
reduction in expression after 7 days followed by an increase back to a
level similar to untreated cells of 76.2±2.6% in 5% O2 cultures at day
35. Culturing at ambient O2 resulted in increasing SPP1 expression
over the culture period with 85.9±2.1% expression at day 35. A
statistically significant difference was seen in SPP1 expression levels
between O2 concentrations at days 7 and 35. Expression of osteocalcin
(BGLAP) (D) was shown to increase in both O2 conditions by day 7
to 81.7±0.6% and 81.4±0.3% respectively and to remain relatively
unchanged in both O2 concentrations for the remainder of the culture.
Core-binding factor subunit beta (E) was seen to show little change in
expression throughout the culture. At day 35 expression levels of 88.8
±0.64% and 90.4±0.2% were seen for 5% and ambient oxygen
cultures respectively. The oxygen tension affected expression levels
significantly at day 7. COL1A1 expression (F) was seen to
dramatically increase by day 7 from untreated levels of 104.9±0.5%
to 125.9±0.2 and 122.8±0.5% for 5% and ambient oxygen tensions
respectively. Levels then declined and at day 35 were 116.3±0.8 and
108.6±0.4 respectively. A significant effect of oxygen tension was
observed on expression levels at each time point. Expression of VDR
(G) was seen to remain virtually unchanged over the 35 day culturing
period. Untreated expression levels were 94±0.6%, with expression
level at day 35 being 96.7±0.4 and 95.7±0.9 respectively. Oxygen
tension displayed a significant effect in cultures at days 7 and 28. A’
shows RUNX2 immunoreactivity in day 14 cultures at ambient O2.
B’, C’ and D’ show COL2A1, SPP1 and BGLAP immunoreactivity
respectively, from day 35 cultures at ambient O2. A”, B”, C” and D”
are quantification of respective antibody staining for each marker over
the 35 day culture period. Positive expression is expressed as
percentage of total cells. RUNX2 expression in both 5% and ambient
O2 cultures was seen to increase by day 14 to 49.0±2.9% and 58.4±
5.0% respectively (A”), followed by a decline and then increase again
towards the end of the culture. COL2A1 was not expressed at early
time points but increased by day 35 in both O2 conditions with 68.4±
4.3% cells positive from ambient O2 cultures (B”). SPP1 was also
seen to increase in expression throughout the culture period with
highest expression seen at day 35 in ambient O2 cultures, with 81.1±
3.0% cells positive (C”). A significant difference between O2
concentrations on SPP1 immunoreactivity was seen at days 14 and
35. BGLAP expression was also seen to increase between days 28 and
35 in both oxygen conditions, and was significant at the different
oxygen conditions at days 14 and 28. By day 35, 70.7±7.6% and 81.1
±3.1% cells were immunoreactive from 5% and ambient O2 cultures
respectively (D”). Student’s t-test. Asterisk(s) indicate levels of
significant difference as follows: *, p<0.05, ** p<0.005, *** p<
0.001. ND = not detected. Scale bars=20 μm. H, H’, H” and H”’
show Alizarin Red S staining of day 35 control and experimental
cultures from both 5% and ambient O2 tensions as labelled. Arrows
show regions of positive Alizarin Red S staining in treated cultures,
thus indicating calcium deposition, an essential feature of osteogenic
differentiation. Scale bars=100 μm
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and differentiated into osteocytes and melanocytes with
high efficiency. Analogous to their equivalent counterparts
in mice, the stem cells are termed human epidermal neural
crest stem cells (hEPI-NCSC).
hEPI-NCSC have many desirable features, the sum of
which makes them a highly attractive type of somatic stem
cell. As remnants of an embryonic tissue, the neural crest,
hEPI-NCSC have the well-recognized physiological ability
to generate a wide array of cell types and tissues. This
innate high level of multipotency, combined with the
expression of pluripotency genes and efficient ex vivo
expansion render this stem cell type conducive not only to
autologous transplantation but potentially also to efficient
reprogramming into iPS cells.
hEPI-NCSC are readily accessible in the hairy skin by
minimal invasive procedure. The patient’s own hEPI-NCSC
could therefore be harvested, expanded ex vivo and then
used for autologous transplantation. hEPI-NCSC are par-
ticularly relevant for treatment in spinal cord injury, as
neural crest stem cells are ontologically closely related to
spinal cord stem cells. Our studies in mouse models of
spinal cord injury showed that EPI-NCSC grafts caused a
significant improvement in sensory connectivity and touch
perception, that they can provide neurotrophic support and
angiogenic activity, and that they possibly modulate scar
formation by synthesis and release of metalloproteases [16,
18]. It is expected that hEPI-NCSC have similar properties.
Bulges can be dissected with ease. Unlike other
procedures [21, 29], the isolation technique does not require
enzymatic digestion, as in the anagen phase the bulge
region reaches into the dermis. Therefore one does not have
to deal with the rather inaccessible, collagen-rich dermis, as
is necessary with isolating stem cells from levels above the
bulge or from intact hair follicles. By taking advantage of
their migratory ability, hEPI-NCSC can be harvested as a
highly pure population of stem cells without an overt need
for further purification, as non-stem cells are not prolifer-
ative and within a short time are outgrown by the stem cells
and left behind upon subculture. Furthermore, optimization
of culture conditions provided bulge explants that produce
emigrating hEPI-NCSC with high yield. Ease of isolation,
high yield, and rapid ex vivo expansion, along with high
purity of the cell population are highly desirable features of
hEPI-NCSC and important considerations for cost-effective
stem cell production.
We show here that hEPI-NCSC express six established
pluripotency genes. Notably, the exact expression levels
vary in a donor-specific manner. Age is unlikely to account
for these differences, as the age bracket of the three donors
tested was 3 years only. The expression of all six
pluripotency genes, C-MYC, KLF4, SOX2, LIN28,
POU5F1/OCT4, NANOG and SOX10 was not expected
and seemingly is unprecedented in somatic stem cells.
Comparison experiments indicate, however, that the genes
are expressed at substantially lower levels in hEPI-NCSC
than in H9 embryonic stem cells. Moreover, it remains to be
determined whether the pluripotency genes are present in
their activated state in hEPI-NCSC. Of particular interest is
the observation that virtually all cells expressed at least four
of the pluripotency genes, C-MYC, LIN28, POU5F1/OCT4
and NANOG. Conversely, the fact that fewer cells
expressed KLF4 and SOX2 indicates that there is hetero-
geneity within the cell population with regard to expression
of pluripotency genes at the protein level.
Interestingly, but not surprisingly, hEPI-NCSC already
express early lineage markers even though they are multi-
potent to a high degree. Expression of early lineage markers
in stem cells has been described previously [19, 44, 49].
Expression of early lineage genes for multiple cell lineages,
that is the neuronal, glial and melanocyte lineages (Fig. 2)
may be an indication that the cells are poised to differ-
entiate into either lineage when exposed to appropriate
cues. This notion is in line with our previous data in mouse
EPI-NCSC, which showed that all cells express both
neuron-specific and glia-specific early lineage genes [18].
Neural crest cells are predestined to give rise to bone and
melanocytes, as they generate craniofacial bone [40, 41]
and pigment cells of the skin and internal organs [31]. We
here show that hEPI-NCSC can be differentiated efficiently
into both osteocytes and into melanocytes. While other
adult stem cells, such as mesenchymal stem cells [32, 34]
and adipocyte stem cells [50, 51] are conducive to bone
differentiation, hEPI-NCSC have the advantage that they
can be accessed fast and safely in the hairy skin as a highly
pure population of stem cells without the need for
enrichment and purification. We conclude from our data
that ex vivo expansion is best carried out at 5% oxygen,
whereas according to most markers tested osteogenic
differentiation is preferably performed at ambient oxygen
tension, as it has been described in the literature [32, 52].
Hair cycles constantly [53]. We have determined that
hair in early and late anagen phase yield hEPI-NCSC.
Epidermal stem cells are known to migrate towards the
matrix [54, 55], where they give rise to new hair. Likewise,
we have observed in mouse hair follicles streams of neural
crest-derived cells that appear to head from the bulge
towards the matrix [13]. hEPI-NCSC are therefore highly
likely to migrate within the hair follicle during anagen
phase, in particular as neural crest-derived melanocytes
differentiate in the matrix of the hair follicle and thus give
hair its colour. During anagen phase, hEPI-NCSC may thus
be in an activated stage, or they may progress into a transit
amplifying-like progenitor cell compartment. The fact that
the dermal sheath needs to cover the bulge in order to
trigger efficient cell emigration from bulge explants
suggests that there are paracrine interactions between the
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bulge and the dermal sheath, an intriguing observation that
warrants further investigation. hEPI-NCSC from different
locations in the body may differ by various criteria. This is
an important notion that needs to be explored in future
studies.
In summary, we have established that hEPI-NCSC are
derived from the neural crest and that they represent a type
of somatic multipotent human stem cell with considerable
potential for future applications in cell-based therapies and
regenerative medicine. The novelty and advantageous
characteristics of hEPI-NCSC include their easy accessibility
in the hairy skin, their high level of purity, their high degree
of multipotency, rapid ex vivo expansion and efficient
directed differentiation into various clinically relevant cell
types. This notion is supported by application trend analysis,
which shows that somatic stem cells are coming to the
forefront with more than 70 human applications in 2009.
Moreover, the final priority value is 60% for adult stem cells
versus 27% and 13% for embryonic stem cells and iPS cells,
respectively, as determined by analytical hierarchy process
[56].
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